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High blood pressure (BP) remains an important clinical problem, as it is a major risk factor for a variety of car-
diovascular diseases.1 However, while for years we have been 
focusing on BP as a main cardiovascular disease symptom, it 
has become apparent that high BP carries a particularly high 
residual risk linked to both vascular and cardiac dysfunction 
and is linked to multi-organ hypertensive pathology.
Ang II (angiotensin II), affects a broad range of processes, 
such as salt and water retention or elevation of vascular con-
tractility and resulting peripheral arterial resistance,2,3 all con-
tributing to BP increase. Chronically elevated BP leads, in 
time, to progressive target-organ damage, for example, in the 
heart manifesting left ventricular (LV) hypertrophy, myocar-
dial ischemia, and heart failure.4
S1P (sphingosine-1-phosphate), a bioactive lysophospho-
lipid produced by Sphks (sphingosine kinases), is a regulator 
of cellular processes such as proliferation,5 migration,6 and 
apoptosis.7 Experimental hypertension results in elevated plasma 
S1P level,8,9 and our, as well as other, studies demonstrated pro-
tection of Sphk1 knockout mice against development of Ang 
II–induced hypertension.8–10 Furthermore, it has been shown 
that mice lacking S1pr2 (sphingosine-1-phosphate receptor 
2) exhibit reduced peripheral vascular resistance as a result of 
impaired vasoconstrictor responses.11 However, mice lacking 
Nogo-B, a transcription factor which inhibits the rate-limiting 
step of de novo sphingolipid synthesis, are hypotensive and re-
sistant to hypertension in response to Ang II due to autocrine 
S1P signaling in endothelium preserving endothelial function.12 
In addition, S1pr1 was identified as a key positive regulator of 
flow-mediated endothelial vasodilation, and EC-specific S1pr1 
downregulation was correlated with increased BP.13
Studies on the cardiac role of S1P/Sphk1 revealed that 
S1P affects cardiac contractility and heart rate, plays an im-
portant role in cardioprotection in response to ischemic injury, 
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and regulates cardiac hypertrophy and fibrosis.14 In vitro stud-
ies have demonstrated that downregulation of Sphk1 signaling 
inhibits TGF-β (transforming growth factor-β)-stimulated col-
lagen production in mouse cardiac fibroblasts.15 Furthermore, 
stimulation of rat neonatal cardiomyocytes with S1P led to cell 
growth in size, and this effect was abolished by S1pr1 antibody 
treatment,16 while mice overexpressing Sphk1 developed sponta-
neous myocardial degeneration and cardiac fibrosis.17 Moreover, 
it was shown that cardiac fibroblast-specific overexpression of 
S1pr1 in mice increases hypertrophy and fibrosis of heart tissue 
which is accompanied by upregulation in Stat3 (signal trans-
ducer and activator of transcription 3) signaling and IL-6 (inter-
leukin-6) production.18 Interestingly, our previous study showed 
that deletion of Sphk1 protects against Ang II–induced cardiac 
hypertrophy.8
The above studies suggest that pharmacological modula-
tion of S1P/Sphk1 signaling may be of interest in the context 
of cardiovascular research. Therefore, the goal of this study 
was to define the effect of pharmacological modulation of 
Sphk1 activity on the development of Ang II–dependent sys-
temic arterial hypertension and associated vascular dysfunc-
tion as well as cardiac hypertrophy by using selective Sphk1 
inhibitor—PF543 in vivo.
Methods
An extended description of the methods is available in the online-
only Data Supplement.
Data Availability Statement
Raw gene counts and final results of the RNA-Seq analysis are 
available as Table in the online-only Data Supplement. Other data 
that support the findings of this study are available from the corre-
sponding author on reasonable request.
Induction of Hypertension and PF543 Treatment In 
Vivo
Male C57BL6/J mice at the age of 12 to 14 weeks bred in spe-
cific pathogen-free facility, fed with standard chow, and randomly 
assigned to the control and treatment groups were investigated. 
Hypertension was induced by 14-day infusion of Ang II (490 ng/
kg per minute, Sigma-Aldrich) using subcutaneously implanted 
osmotic minipump (Alzet) following intraperitoneal anesthesia 
with Ketamine (100 mg/kg)/xylazine (10 mg/kg) solution (both 
Biowet, Poland). Two models of PF543 treatment were tested: 
(1)a rescue model—a single intraperitoneal injection with PF543 
(Cayman Chemical) at a dose of 10 mg/kg (dissolved in 20% 
β-hydroxypropyl-cyclodextrin in PBS) of normotensive mice or hy-
pertensive mice (on the 13th day of continuous Ang II infusion) and 
(2)a chronic model—injected PF543 intraperitoneally every 2 days 
(at a dose of 1 or 10 mg/kg) commencing the day before implan-
tation of the Ang II–dosed pump. Importantly, MacRitchie et al19 
demonstrated that application of the higher PF543 dose (ie, 10 mg/
kg) degrades Sphk1 in pulmonary vessels in mice,19 while Zhang 
et al20 found that lower, 1 mg/kg, dose of PF543 inhibits murine 
cardiac sphingosine kinase activity and lowers serum S1P content. 
Mice underwent noninvasive systolic BP measurement by tail-cuff 
plethysmography (Visitech BP 2000 BP Analysis System) before 
commencement of the treatment and during hypertension develop-
ment. After 2 weeks of Ang II infusion, mice were euthanized, tis-
sues were collected and subjected to subsequent experiments. For 
RNA and protein isolation, tissues were lysed in dedicated buffers21 
(see online-only Data Supplement for details). If possible, experi-
ments were performed on blinded samples. All experiments were 
approved by the II Local Ethics Committee in Cracow (approval 
number 157/2016).
RNA-Seq Analysis
To recapitulate possible changes in transcriptome profile caused by down-
regulation of S1pr1, we studied LV samples obtained from hypertensive 
mice treated either with 10 mg/kg per 2 days PF543 dose or placebo. Total 
RNA from the LV of hypertensive mice, chronically treated with either 
PF543 (intraperitoneal 10 mg/kg every 2 days; n=4) or solvent control 
(n=4), was isolated using Direct-zol RNA Miniprep kit and treated with 
DNase I (Zymo Research). Briefly, mRNA was isolated using NEBNext 
Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). The 
mRNA library was prepared using NEBNextUltra II Directional RNA 
Library Prep Kit for Illumina. Sequencing was performed with HiSeq4000 
(Illumina) with 150 bp paired-end reads (PE150). Bioinformatic analysis 
included trimming of adapters, polyA, and polyT tails using Cutadapt.22 
RNA-seq reads were then mapped to genes according to the reference ge-
nome (Mus musculus M20, GRCm38.p6 downloaded from GENCODE) 
using TopHat software.23 Reads were counted with HTseq.24
Histological Analysis of Cardiac Tissues
Formalin-fixed and paraffin embedded 7 µm sections were deparaf-
finized and rehydrated. Sections were stained with Weigert’s iron he-
matoxylin solution (Sigma-Aldrich) for 10 minutes and then washed 
and incubated in the dark with 0.1% Sirius red F3B (Sigma-Aldrich) 
for 1 hour, washed in acidified water, dehydrated, and mounted. 
Additionally, fixed tissue was also stained with Masson’s trichrome 
(Sigma-Aldrich, Germany) according to the manufacturer protocol. 
The cross-sectional cardiomyocyte size was calculated using cells 
with integral membrane and visible nucleus (≈60 cells per section). 
Relative fibrotic area and cardiomyocyte size quantification was per-
formed using ImageJ (version 1.49) software.25
Measurement of Cardiac Sphingosine Content
Heart tissues were homogenized and subjected to lipid extraction by 
a modified 1-step Bligh and Dyer protocol.26,27 Then, samples un-
derwent chemical methylation.28,29 Samples were analyzed in posi-
tive ion mode using a Q Exactive mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA) equipped with a TriVersaNanoMate (Advion 
Biosciences, Ithaca, NY). The acquisition cycle consisted of Fourier-
transform mass spectrometry (FT MS) and targeted Fourier-transform 
tandem mass spectrometry (FT MS/MS) scans in the positive mode. 
Acquired data were processed by using LipidXplore software.30 More 
details are provided in the online-only Data Supplement.
Statistical Analysis
Differential gene expression analysis from the RNA-Seq experi-
ment was performed using DESeq2 package in R (version 3.5.1),31 
while Overrepresentation Enrichment Analysis was performed using 
WebGestalt32 and all 599 genes with false discovery rate (FDR) corrected 
P value <0.05 (Table in the online-only Data Supplement for a sum-
mary statistics of all genes detected in the RNA-Seq analysis). To check 
whether and how chronic PF543 treatment affected cardiac processes re-
lated to cell death, we performed overrepresentation analysis separately 
for genes significantly (FDR, P<0.05) up- or downregulated. Repeated 
measures ANOVA was used for analysis of vascular function studies and 
BP measurements, and t tests were used for analysis of mRNA/protein ex-
pression data. All these statistical tests were performed using IBM SPSS 
Statistics (version 25) or GraphPad Prism (version 7). Data are presented 
as means±SEM. P values<0.05 were considered statistically significant.
Results
Effects of PF543 Treatment on the Development of 
Ang II–Dependent Hypertension and Associated 
Cardiac Remodeling
The results revealed that PF543 did not affect systolic BP level 
during chronic administration in mice developing hypertension 
using either 1 or 10 mg/kg per 2 days doses (Figure 1A) or 24 
hours after drug injection when hypertension was already es-
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not change blood pressure level of normotensive mice (Figure 
S1A). Interestingly, chronic PF543 treatment in hyperten-
sive mice significantly reduced cardiac mass, suggesting that 
Sphk1 may play a role in the regulation of cardiac remodeling 
in response to Ang II–dependent hypertension (Figure 1B).
Molecular Mechanisms of Cardiac PF543 Action
Using mass spectrometry analysis, we found that the level of 
possible S1P precursors, that is, sphingoid bases (16:2 and 
20:1 species) was significantly elevated in the LV of PF543-
treated as compared with placebo-treated hypertensive 
Figure 1. Effects of chronic PF543 treatment on the development of Ang II (angiotensin II)–induced hypertension and cardiac hypertrophy. A, Systolic blood 
pressure (SBP) of Sham or Ang II–infused (490 ng/kg per min) mice treated either with PF543 (1 mg/kg or 10 mg/kg every 2 days) or placebo (solvent). n=8, 
17, 13, 11 for Sham, Ang II+placebo, Ang II+PF543 1 mg/kg, Ang II+PF543 10 mg/kg group, respectively. B, Heart to body weight ratio (mg/g) of Sham 
or Ang II–infused (490 ng/kg per min) mice treated either with PF543 (1 or 10 mg/kg every 2 days) or placebo. n=8–18/group. C, Measurement of different 
sphingoid bases content, normalized to total protein concentration, in the left ventricular heart tissue of Ang II–infused mice treated either with PF543 (10 
mg/kg every 2 days) or placebo, using mass spectrometry. n=4/group. D, Heatmap of 51 genes significantly up- or downregulated (an absolute fold change 
higher than 1.8) in the left ventricular heart tissue of Ang II–infused mice treated either with PF543 (10 mg/kg every 2 days) or placebo. Transcriptome analysis 
was performed using RNA-Seq method. n=4/group. E, Results of overrepresentation enrichment analysis based on 599 genes with significantly changed 
expression in the left ventricular heart tissue of Ang II-infused after chronic PF543 (10 mg/kg every 2 days) treatment. F, Expression of cardiac hypertrophy-
related genes was quantified using real-time polymerase chain reaction in the LV of Sham and Ang II–infused mice treated either with PF543 (1 or 10 mg/
kg every 2 days) or placebo. n=9 to 13/group. $P<0.05 as indicated, *P<0.05 vs all other groups, **P<0.05 vs Sham or Ang II+PF543 10 mg/kg groups, and 
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animals (Figure 1C), which confirms that PF543 changes 
sphingolipid balance in the heart. This may have global 
consequences with respect to the cardiac transcriptome 
in hypertension. To address this, we performed RNA-Seq 
analysis, which identified 599 genes significantly up- or 
downregulated in response to PF543 in LV tissue (Table 
in the online-only Data Supplement), including 51 with an 
absolute fold change higher than 1.8 (Figure 1D). RNA-
Seq analysis demonstrated a significant, PF543-mediated 
downregulation of expression of genes such as fibronectin 1 
(Fn1), integrin subunit α-5 (Itga5) and integrin subunit β-3 
(Itgb3), connective tissue growth factor (Ctgf), actinin α-1 
(Actn1) or fetal genes myosin heavy chain 7 (Myh7), and 
natriuretic peptide B (Nppb; Table in the online-only Data 
Supplement).
Subsequent pathway analysis revealed that PF543, among 
other processes, primarily affected actin filament organiza-
tion and binding, TNF (tumor necrosis factor) superfamily 
cytokine production, and tissue remodeling in hypertensive 
animals (Figure 1E). Real-time polymerase chain reaction 
experiments confirmed that PF543 treatment reduced mRNA 
expression of genes from the above pathways accompanying 
cardiac remodeling such as Ctgf, Tgfβ1, α- smooth muscle 
actin 2 (Acta2), β- actin (Actb), interleukin-6 (Il-6), and TNF 
receptor superfamily member 11b (Tnfrsf11b) in hypertensive 
animals (Figure 1F).
None of the pathways related to necrosis, apoptosis or 
autophagy were significantly (FDR, P<0.05) enriched while 
analyzing genes up- or downregulated by PF543 treat-
ment. We identified 4 pathways related to apoptosis that 
were enriched among genes significantly downregulated by 
PF543 treatment at FDR P<0.2 (Figure S2A). Additionally, 
Western blot analysis showed that chronic PF543 treatment 
did not change protein level of the apoptotic marker, that 
is, cleaved form of PARP (poly [ADP-ribose] polymerase; 
Figure S2A).
Given the fact that RNA-Seq analysis revealed that genes 
and pathways related to cardiac hypertrophy and fibrosis were 
altered after PF543 treatment (eg, collagen genes [Col1a1 and 
Col3a1] were downregulated (unadjusted P<0.05, Table in the 
online-only Data Supplement), we performed histological ex-
amination of cardiac sections. However, this analysis showed 
no significant effects of PF543 treatment on cardiac fibrosis 
in Ang II–infused mice (Figure 2A). On the contrary, PF543 
treatment significantly reduced cardiomyocyte size in hyper-
tensive animals (Figure 2B). Additionally, protein quantifica-
tion by Western blot confirmed a significant upregulation of 
hypertrophic markers- Acta2 and Fn1 after Ang II infusion, 
and this effect was attenuated by PF543 treatment (Figure 2C).
PF543 Modulates Key Signaling Pathways Involved 
in Cardiac Hypertrophy
Ang II treatment significantly induced expression of cardiac 
S1pr1 and S1pr2, but not S1pr3, as compared with Sham an-
imals (Figure S1B). Notably, an initial, rescue experiment 
testing an acute effect of single PF543 injection demonstrated 
significantly decreased type 1 S1P-receptor (S1pr1), but not 
S1pr2 or S1pr3 mRNA expression in cardiac tissue 24 hours 
after drug injection (Figure S1B), which was confirmed by 
Western blot analysis (Figure S1C). Such decrease in S1pr1 
expression may be regarded as specific for hypertensive con-
ditions as in normotensive mice single injection with PF543 
did not affect S1pr1 protein level (Figure S1D).
Similarly, compared with a single PF543 injection, 
we found that chronically administered PF543 signifi-
cantly reduced S1pr1 protein expression level in the heart 
(Figure 3A). Interestingly, no significant effects on mRNA ex-
pression of S1pr1 or other S1P receptors in hypertensive mice 
were observed (Figure 3B). Additionally, although chronic 
PF543 administration reduced mRNA levels of Sphk1 in hy-
pertensive animals (Figure S3A), it did not change Sphk1 
protein levels (Figure S3B). We found that Sphk activity was 
significantly increased in cardiac tissue of hypertensive mice 
as compared with Sham, while chronic PF543 treatment (10 
mg/kg) decreased enzyme activity in hypertensive hearts 
(Figure S3C).
To investigate the mechanism of PF543 action in hyper-
trophic heart in more detail, we examined expression level 
of proteins potentially involved in cardiac S1P signaling. 
Western blot analyses demonstrated that in the hypertrophic 
heart of Ang II–infused mice there was a significant upregula-
tion of Rock1 (Rho-associated coiled-coil containing protein 
kinase 1) and phosphorylated forms of Stat3, PKC (protein 
kinase C) and ERK1/2 (extracellular signal-regulated kinases 
1/2) signaling molecules as compared with Sham animals 
(Figure 4). Importantly, chronic PF543 treatment prevented 
the above changes in hypertensive animals (Figure 4). In con-
trast, chronic PF543 treatment in hypertensive mice did not 
affect the phosphorylation pattern of Akt and GSK3β (gly-
cogen synthase kinase 3-β) signaling kinases (Figure S2B).
Independent experiments on LV tissue derived from nor-
motensive and Ang II–infused hypertensive or Ang II–infused 
hypertensive mice treated either with PF543 (10 mg/kg per 2 
days) or placebo supported inhibitory effect of PF543 treat-
ment in vivo on the Ang II–induced increment in cardiac 
Rock1 and S1pr1 expression, as well as activation status of 
Stat3 and ERK1/2 (Figure S4; Figure S5 for a wide version of 
Western blot images of all cardiac proteins analyzed).
Effects of PF543 Treatment on the Ang II–
Dependent Vascular Dysfunction In Vivo
Ex vivo tests revealed that adding 10 µmol/L to the myograph 
chamber does not constrict mesenteric arteries derived from 
normotensive mice. Instead, such arteries, preconstricted 
with U-46619, relax in response to increasing doses of PF543 
(Figure S6A). Subsequent experiments involving in vivo ad-
ministration of PF543 demonstrated no changes in contractile 
responses of mesenteric arteries of hypertensive mice after 
chronic PF543 treatment (Figure S6B). However, chronic 
administration of Sphk1 inhibitor significantly improved 
acetylcholine-, but not sodium nitroprusside-, mediated vaso-
relaxation of such arteries (Figure S6C). The above effect 
was accompanied by a significantly decreased expression of 
phosphorylated forms of eNOS (T495) and ERK1/2 (T202/
Y204; Figure S7A), while no changes in Rock1 protein level 
or in phosphorylation of PKC at Serine(S) 660 after PF543 
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Ang II induced expression of Sphk1 mRNA in mesenteric 
arteries as compared with the Sham group; however, PF543 
had no further effect on its expression in hypertensive mice 
(Figure S7C). No differences in Nos3 mRNA expression were 
observed between all groups (Figure S7C). Although Ang II 
infusion did not affect mRNA level of S1P receptors as com-
pared with the Sham group, PF543 triggered an upregulation 
of S1pr2 and downregulation of S1pr3 mRNA in mesenteric 
arteries of hypertensive mice of relatively little magnitude, 
that is, increment 1.23× and 1.33× of S1pr2 expression in Ang 
II+PF543 (1 mg/kg per 2 days) and Ang II+PF543 (10 mg/kg 
per 2 days), respectively, versus Ang II+placebo and 1.31× 
decrement of S1pr3 mRNA expression in Ang II+PF543 (10 
mg/kg per 2 days) versus Ang II+placebo (Figure S7C). As 
among other S1P receptors S1pr1 plays major role in the reg-
ulation of endothelial vasorelaxation, we tested S1pr1 protein 
level. Results showed no significant difference in S1pr1 pro-
tein level between PF543-treated and placebo-treated hyper-
tensive mice (Figure S7D). Moreover, there were no significant 
differences in arterial expression of genes related to vascular 
remodeling, that is, Fn1, Col1a1, and Col3a1 between PF543- 
and placebo-treated hypertensive animals (Figure S7C).
PF543 and S1P Affect eNOS Phosphorylation In 
Human Endothelial Cells
PF543 treatment significantly downregulated SPHK1 pro-
tein expression by >80% and decreased P-eNOST495 expres-
sion in human microvascular endothelial cells (Figure S8A). 
Additionally, in line with the above results, elevated phospho-
rylation at the eNOS (T495) site after 24 hours stimulation of 
endothelial cells with S1P was observed (Figure S8B). No sig-
nificant changes in phosphorylation of ERK1/2 or PKC were 
observed after PF543 treatment for 24 hours (Figure S8A). On 
the contrary, stimulation of endothelial cells with S1P for 24 
hours significantly increased P-ERK1/2T202/Y204 and decreased 
PKC phosphorylation level at the S660 site (Figure S8B).
Discussion
In the present study, we demonstrate that pharmacological 
inhibition of Sphk1 activity modulates vascular function and 
reduces cardiac hypertrophy induced by Ang II. The latter 
effect is accompanied by RNA-Seq-quantified downregu-
lation of cytoskeletal, ECM, and TNFα-related genes and 
may be mediated by the elevation of cardiac sphingosine 
content and downregulation of S1pr1 and PKC, as well as 
Figure 2. PF543 treatment affects cardiomyocyte hypertrophy and associated Fn1 and Acta2 (α-smooth muscle actin 2) expression with no effects on 
cardiac fibrosis. A, PicroSirius staining of the heart sections used to quantify the percentage of fibrotic area in the cardiac tissue. Percentage of fibrosis is 
shown relative to the area of heart section. n=4–8/group. B, Masson’s trichrome staining of the heart sections used to quantify cardiomyocytes area. n=4–8/
group. C, Protein expression of fibronectin 1 and Acta2 studied by Western blotting in the cardiac tissue of Ang II (angiotensin II)-infused (490 ng/kg per 
min) mice treated either with PF543 (1 or 10 mg/kg every 2 days) or placebo. Densitometric analysis of protein normalized to Gapdh is shown. n=3–4/group. 
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pro-hypertrophic markers such as Stat3. This extends our pre-
vious, transcriptomic study that identified Sphk1 as a mod-
ulator of Ang II–dependent vascular dysfunction and as a 
potential regulator of cardiac hypertrophy development in re-
sponse to pressure overload in vivo.8
A growing body of literature show that the Sphk1/
S1P pathway plays an important role in the cardiovascular 
system.33–36 MacRitchie et al19 demonstrated that PF543 
degrades Sphk1 in pulmonary vessels in vivo, without effect-
ing Sphk1 expression in the heart, which is in agreement with 
our results. Another study by Zhang et al20 found that chronic 
administration of PF543 reduces serum and cardiac levels of 
S1P in Sham and in post-myocardial infarction mice, which is 
associated with improved LV ejection fraction. This supports 
the previous study by Polzin et al37 who demonstrated a nega-
tive correlation between LV ejection fraction and plasma S1P 
levels among patients with ischemic heart disease. We found 
that PF543 treatment increases sphingosine content and lowers 
cardiac S1pr1 expression in cardiac tissue, and both phenomena 
might be caused by various events including Sphk1 inhibition 
in cardiac tissue or a decrease in serum S1P level, a known con-
sequence of PF543 action in vivo.20,38 This extends results of 
another in vitro study showing a simultaneous decrease in S1P 
and an increase in sphingosine content in 1483 cells exposed to 
PF543.39 Moreover, the above results are in line with significant 
downregulation of sphingosine kinase activity in cardiac tissue 
after PF543 treatment in vivo observed in the current study.
Regardless of the strategy of administration (acute or 
chronic injection), PF543 did not affect the level of systolic 
BP in mice developing or with established hypertension. On 
the contrary, our findings identified PF543 as a vasorelax-
ant agent ex vivo and demonstrated a clear linkage between 
pharmacological administration of PF543 and improvement 
of mesenteric artery function in hypertensive mice in vivo. 
We found a decreased phosphorylation of eNOS at T495, 
known as an inhibitory for eNOS activation, NO production 
and endothelium-dependent vasorelaxation,40,41 as a possible 
cause of improved mesenteric artery function after PF543 
treatment in hypertensive mice. Furthermore, the effect of 
PF543 seems to be independent of S1pr1 expression level. 
We also found significant differences in S1pr2 and S1pr3 
mRNA expression after PF543 chronic treatment in mesen-
teric arteries. Although it is known that signaling mediated by 
S1pr2/S1pr3 is important for contraction of vascular smooth 
muscle cells and that S1pr3 positively regulates endothelial 
vasorelaxation,36 it should be noted that the magnitude of 
changes in the expression of these receptors observed in our 
study was relatively small and did not result in changes of 
arterial contraction or exaggeration of endothelial dysfunc-
tion as demonstrated in vascular function studies. The lack 
of effect of PF543 treatment on vascular contraction may at 
least partially explain no significant effects observed with 
regards to BP level during hypertension development.
Among kinases targeting eNOS at T495 such as PKC,42 
Rock1,43 and ERK1/2,41,44 only expression of the phosphory-
lated ERK1/2 was attenuated by chronic PF543 treatment. 
Moreover, downregulation in T495 eNOS phosphorylation in 
response to PF543, which mimics inhibition of autocrine S1P 
signaling, was observed also in vitro in human primary mi-
crovascular endothelial cells. Stimulation of these cells with 
S1P, which mimics upregulation of endocrine S1P signaling in 
vivo, evoked the opposite effect and hence confirmed that S1P 
regulates eNOS activity by its phosphorylation at T495. While 
PF543 did not affect ERK1/2 or PKC phosphorylation level, 
S1P stimulation significantly upregulated P-ERK1/2, which 
confirms previous findings by Igarashi et al.45 In summary, 
Figure 3. Chronic PF543 treatment downregulates cardiac S1pr1 protein expression in Ang II (angiotensin II)–infused hypertensive mice. A, Protein 
expression of S1pr1 studied by Western blotting in the left ventricular tissue of Sham and Ang II–infused (490 ng/kg per min) mice treated either with 
PF543 (1 mg/kg or 10 mg/kg every 2 days) or placebo. Densitometric analysis of S1pr1 normalized to Gapdh is shown. n=3–4/group. B, Expression of 
S1pr1, S1pr2, and S1pr3 was quantified using real-time polymerase chain reaction in the hearts of normotensive (Sham) and hypertensive (Ang II–infused) 
mice treated either with PF543 (1 mg/kg or 10 mg/kg every 2 days) or placebo. n=9–13/group. *P<0.05 vs Sham or Ang II+PF543 10 mg/kg groups, 
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these findings show that a relative improvement of endothelial 
function caused by PF543 is not sufficient to compensate for 
other Ang II–stimulated mechanisms contributing to the de-
velopment of experimental hypertension.
A 2-week infusion of Ang II resulted in the development 
of cardiac hypertrophy. Ang II triggered an upregulation of 
fibronectin 1, an important stimulator of cardiomyocyte hy-
pertrophic growth,46 which action is transduced by membrane 
heterodimeric integrin receptors composed of an α and β chain. 
Pharmacological inhibition of Sphk1 by PF543 prevented Ang 
II–induced transcript upregulation of fibronectin 1, integrins 
(Itga5 and Itgb3), Ctgf, Tgf-β1, and fetal hypertrophy markers 
Nppb and Myh7 in hypertensive animals. Since PF543 signif-
icantly reduced cardiomyocyte size in hypertensive animals, 
we conclude that PF543 may serve as a potential antihyper-
trophic agent due to its effect on S1P/sphingosine balance in 
cardiac tissue and serum,20,38 and its action may be mediated 
by both S1P-receptor dependent and independent pathways.
Spatial distribution of S1P receptors in the heart is an im-
portant determinant of specific S1P action in different car-
diac tissue compartments. While cardiac fibroblasts express 
mainly S1pr3, cardiomyocytes are characterized by abundant 
S1pr1 expression.14 Our results indicate that reduced car-
diac hypertrophy due to PF543 treatment may be mediated, 
at least partially, by a downregulation of S1pr1 expression. 
This result ties well with previous studies where S1pr1 an-
tibody treatment prevented S1P-induced increase in the size 
of rat neonatal cardiomyocytes,16 and genetic overexpression 
of S1pr1 in myofibroblasts exaggerated cardiac hypertrophy 
in an Ang II–dependent manner in vivo.18 Since we did not 
observe significant effects of PF543 on cardiac fibrosis in hy-
pertensive mice, as assessed by collagen-staining method, it 
can be concluded that pharmacological inhibition of Sphk1 
affects Ang II–dependent cardiac hypertrophy rather than 
fibroblast-mediated deposition of collagen. This is in line 
with our previous study that investigated the Sphk1 knockout 
mouse for these effects.8
To further investigate the mechanism of attenuation 
of Ang II–dependent cardiac hypertrophy by PF543, we 
checked the activation status of various signaling molecules. 
A positive correlation of Ang II infusion with elevated ac-
tivity of signaling molecules such as Rock1, Stat3, PKC, 
Figure 4. Chronic PF543 treatment downregulates Rock1 (Rho-associated coiled-coil containing protein kinase 1), P-Stat3 (signal transducer and activator 
of transcription 3), P-PKC (protein kinase C), and P-ERK1/2 (extracellular signal-regulated kinases 1/2) in cardiac tissue of Ang II (angiotensin II)-infused 
hypertensive mice. Protein expression of Rock1, p-Stat3Y705, P-PKCPanβII660, P-ERK1/2T202/Y204 and Gapdh studied by Western blotting in the hearts of Sham 
or Ang II–infused (490 ng/kg per min) mice treated either with PF543 (1 mg/kg or 10 mg/kg every 2 days) or placebo. Densitometric analysis of proteins 
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Akt, and ERK1/2 in the hypertrophic heart was observed. 
Crucially, pharmacological inhibition of Sphk1 with PF543 
remarkably downregulated Rock1, as well as decreased the 
activation status of Stat3, PKC, and ERK1/2. Rock1 is an 
important positive regulator of cardiomyocyte apoptosis and 
cardiac fibrosis; thus it is considered as potential therapeutic 
target for limiting the progression to heart failure.47 Stat3 is 
a transcription factor regulating the expression of cardio-
protective genes associated with the adaptation of the heart 
to stress conditions.48 Activation of Stat3 in pressure-over-
loaded cardiac myocytes is primarily mediated by the auto-
crine/paracrine release of IL-6 and TNF-α, and to a lesser 
extent, by the local production of Ang II.49 Importantly, it 
was also revealed that activation of Stat3 in neonatal rat 
ventricular cardiomyocytes is induced by increasing the 
dose of S1P, and this effect is mediated by upregulation of 
P-ERK1/2. Additionally, S1P-mediated ERK1/2 and Stat3 
activation was partially reversed by treatment with an inhib-
itor of Rock (Y27632), which points to Rock as a potential 
mediator in S1P signaling in cardiomyocytes.50 Moreover, 
several studies demonstrated that both canonical (α, β) and 
novel isoforms (δ, ε) of PKC regulate pathological cardiac 
remodeling.51 Importantly, sphingosine is a known PKC in-
hibitor, and higher sphingosine content in LV tissue induced 
by PF543 treatment may explain PF543-induced downregu-
lation of cardiac PKC phosphorylation.
As S1P in the heart has been considered cardioprotec-
tive,14 questions arise as to whether reduced cardiac hyper-
trophy after chronic PF543 treatment does not result from 
enhanced cell death. However, RNA-Seq analysis of cardiac 
transcriptome, as well as determination of the level of markers 
and mediators of cardiac apoptosis and myocyte survival (ie, 
PARP, P-Akt, and P-GSK3β) demonstrated no significant dif-
ferences between placebo and PF543-treated mice.
Inclusion of exclusively male animals may be considered 
as a limitation of our study. This was associated with the fact 
that Ang II infusion is best characterized as model of hy-
pertension in male mice.52 Studies demonstrated that Ang II 
induces considerably greater blood pressure increase in male 
than in female subjects, and that sex hormones are important 
mediators of hypertension pathogenesis.53 Moreover, there is a 
higher plasma S1P level in woman, as well as in female mice 
than in males or male mice, respectively.54 Considering the fact 
that some of the mechanisms investigated in the current study 
may be altered by the above mentioned sex-mediated differ-
ences, it remains to be established whether similar, cardiac 
effects of PF543 treatment can be observed in female mice 
that are at least partially protected against Ang II–induced hy-
pertension due to various hormone- and immunology-related 
factors.55 Future studies are needed to characterize sex-depen-
dent differences in S1P biology in hypertension.
Perspectives
PF543 has an anti-hypertrophic potential as it partially pro-
tects against pathological changes that occur in the heart dur-
ing Ang II–dependent hypertension in mice. Its action may be 
mediated by specific downregulation of S1P type 1 receptor 
expression, as well as by sphingosine accumulation in the 
cardiac tissue as a result of Sphk1 inhibition. PF543 triggers 
downregulation of important cardiac hypertrophy-related 
pathways mediated by Rock1, Stat3, PKC, and ERK1/2. 
Furthermore, PF543 partially inhibits changes in the ex-
pression of actin-, TNFα-, and tissue remodeling–associated 
genes that are characteristic for the hypertrophic heart. Thus, 
SPHK1 inhibition might be a pharmacological strategy to pre-
vent cardiac hypertrophy in patients with newly diagnosed 
hypertension. Chronic rather than acute effects of SPHK1 in-
hibition are more likely.
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What Is New?
•	Pharmacological inhibition of Sphk1 (sphingosine kinase 1) with PF543 
reduces endothelial dysfunction in the arteries from Ang II (angiotensin 
II)–infused, hypertensive mice as compared with placebo-treated con-
trols with no effect on systolic blood pressure level. This effect is asso-
ciated with a downregulation of ERK1/2 (extracellular signal-regulated 
kinases 1/2) signaling and a reduction of inhibitory eNOS (endothelial 
nitric oxide synthase) phosphorylation at T495.
•	PF543 chronic treatment reduces cardiac hypertrophy in Ang II–infused, 
hypertensive mice. Mechanisms of action may be partially mediated by 
the downregulation of S1pr1, Rock1 (Rho-associated coiled-coil contain-
ing protein kinase 1), Stat3 (signal transducer and activator of transcrip-
tion 3), PKC (protein kinase C), and ERK1/2 signaling.
•	PF543 chronic treatment reduces expression of cardiac actin-, TNF-α 
(tumor necrosis factor-α)-, and tissue remodeling–associated genes that 
are upregulated by Ang II.
What Is Relevant
•	Our results demonstrate novel, pharmacological effects of Sphk1 inhibi-
tion in the cardiovascular system of hypertensive mice.
Summary
PF543 has anti-hypertrophic properties as it partially protects 
against pathological hypertrophic changes that occur in the 





 http://ahajournals.org by on D
ecem
ber 21, 2020
